Start-up Inflazome Announces Acquisition by Roche
Orally available NLRP3 inflammasome inhibitors to address clinical unmet needs across a wide variety of inflammatory diseases
22-Sep-2020 -
Inflazome announced that it has closed a share purchase agreement with Roche in which Inflazome’s shareholders received an upfront payment of €380 million, and are eligible to receive additional contingent payments to be made based on the achievement of certain predetermined milestones. ...
acquisitions
inflammasomes
inhibitors
+1